# Alemtuzumab for ANCA Associated Refractory Vasculitis

> **NCT01405807** · PHASE4 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 24 (estimated)

## Conditions studied

- Vasculitis
- Microscopic Polyangiitis
- Granulomatosis With Polyangiitis
- Wegener's

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT01405807
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405807, "Alemtuzumab for ANCA Associated Refractory Vasculitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01405807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*